Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Bone Marrow Transplant. 2021 Apr;56(4):974-977. doi: 10.1038/s41409-020-01099-4. Epub 2020 Nov 10.

¹ Department of Hematology Oncology, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. Snghafouri@mednet.ucla.edu.
² UCLA Lymphoma Program, Division of Hematology & Oncology, Department of Medicine, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
³ Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
⁴ Department of Hematology Oncology, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.

No abstract available

Publication types